Last C$0.90 CAD
Change Today -0.09 / -9.09%
Volume 125.3K
IM On Other Exchanges
Symbol
Exchange
Toronto
NASDAQ GS
Frankfurt
As of 4:00 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

imris inc (IM) Snapshot

Open
C$1.00
Previous Close
C$0.99
Day High
C$1.00
Day Low
C$0.88
52 Week High
02/26/14 - C$3.20
52 Week Low
06/5/14 - C$0.86
Market Cap
46.8M
Average Volume 10 Days
35.5K
EPS TTM
C$-0.77
Shares Outstanding
52.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMRIS INC (IM)

Related News

No related news articles were found.

imris inc (IM) Related Businessweek News

No Related Businessweek News Found

imris inc (IM) Details

IMRIS Inc. designs, manufactures, and sells image-guided therapy solutions that enable surgeons to obtain information and make decisions during the course of procedures. The company offers VISIUS Surgical Theatres, which deliver detailed visual information to clinicians during the course of various traditional surgical procedures that is used for various surgical applications, such as neurological, cardiovascular, cerebrovascular, interventional, and spine. The company’s products in development include magnetic resonance (MR) guided radiation therapy systems for use in MR imaging during radiotherapy treatments for cancer; and image guided surgical robotic systems for use in neurosurgical procedures. The company serves hospitals worldwide. IMRIS Inc. is based in Winnipeg, Canada.

137 Employees
Last Reported Date: 03/4/14

imris inc (IM) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $421.0K
Chairman
Total Annual Compensation: $253.8K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $286.4K
Executive Vice President of Operations
Total Annual Compensation: $250.0K
Chief Technology Officer and Executive Vice P...
Total Annual Compensation: $276.7K
Compensation as of Fiscal Year 2013.

imris inc (IM) Key Developments

Kelly McNeill, Executive Vice President, Finance and Chief Financial Officer Leaves IMRIS, Inc., September 5, 2014

IMRIS Inc. announced that Kelly McNeill, Executive Vice President, Finance and Chief Financial Officer, will be leaving the company. Mr. McNeill has decided to remain in Winnipeg and not relocate to the Company's new corporate office in Minnesota. McNeill has served as IMRIS' CFO since September 2009. He will remain with IMRIS through September 5, 2014.

Japanese Patent Office Grants Patents to IMRIS

IMRIS, Inc. announced the granting of three patents by the Japanese patent office related to key technology currently integrated into its intraoperative MRI (iMRI) solution within the VISIUS Surgical Theatre. The patents cover control of effective MR imaging using a movable system; imaging coils where clarity is maintained when used while in position during x-ray use; and other components related to using both MR and x-ray imaging in the same environment. The covered technology is utilized in VISIUS Surgical Theatres which are hybrid operating room suites with iMRI where a diagnostic quality scanner moves to the patient using ceiling-mounted rails. VISIUS iMRI hybrid ORs may also include x-ray angiography systems where both types of imaging are desired. The fully integrated suites provide neurosurgeons on-demand access to high resolution images - before, during and after procedures without moving the patient from the OR table for truly intraoperative imaging and improved treatment outcomes. During brain tumor procedures, serial scanning gives the surgeon the ability to assess results and perform further resection to remove as much tumor as possible. Clinical studies indicate a link between more complete removal of some types of tumors and longer life expectancy and quality of life. IMRIS also develops and manufactures proprietary intraoperative CT systems, head fixation devices, imaging coils, and OR tables for use in this unique and multifunctional intraoperative environment.

IMRIS, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Third Quarter, Full Year of 2014 and Full Year of 2015

IMRIS, Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported sales of $4,258,000 compared to $10,226,000 a year ago. Operating loss was $6,782,000 compared to $7,707,000 a year ago. Net loss was $7,027,000 compared to $8,203,000 a year ago. Adjusted LBITDA was $5,676,000 compared to $6,260,000 a year ago. Basic and diluted loss per share was $0.14 compared to $0.16 a year ago. For the six months, the company reported sales of $12,409,000 compared to $18,292,000 a year ago. Operating loss was $12,901,000 compared to $15,481,000 a year ago. Net loss was $14,928,000 compared to $16,581,000 a year ago. Adjusted LBITDA was $10,592,000 compared to $12,632,000 a year ago. Basic and diluted loss per share was $0.29 compared to $0.34 a year ago. Net cash used in operating activities were $2,277,000 against $21,560,000 a year ago. Acquisition of property, plant and equipment was $1,850,000 against $5,067,000 a year ago. The company provided earnings guidance for the third quarter, full year of 2014 and full year of 2015. For the period, the company expects revenues to be in the range of $6 million to $7 million. For the full year, the company expects revenues in the range of $30 million to $34 million, compared with the previous range of $44 million to $46 million. The company continues to expect improved 2014 full-year gross profit performance against the prior year. The company anticipates a gross profit margin of approximately 35% to 36%. Total capital expenditures in 2014 are anticipated to be approximately $2.5 million. Total operating expenses expected to be of $33.0 million. For the full year of 2015, the company anticipates revenues of approximately $60 million to $65 million, reflecting growth in the business and the timing of installations from 2014 to 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IM:CN C$0.90 CAD -0.09

IM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
General Electric Co $25.98 USD -0.03
Koninklijke Philips NV €23.19 EUR -0.10
Medtronic Inc $63.85 USD +0.73
Siemens AG €95.17 EUR +0.32
View Industry Companies
 

Industry Analysis

IM

Industry Average

Valuation IM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.2x
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMRIS INC, please visit www.imris.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.